A Study to Evaluate the Safety, Pharmacokinetics, and Activity of Enzelkitug as a Single Agent and in Combination With Checkpoint Inhibitor in Participants With Locally Advanced or Metastatic Solid Tumors | MicrobiomeTrials
A Study to Evaluate the Safety, Pharmacokinetics, and Activity of Enzelkitug as a Single Agent and in Combination With Checkpoint Inhibitor in Participants With Locally Advanced or Metastatic Solid Tumors
RecruitingPHASE1INTERVENTIONAL
Trial Details
Start: 2022-10-20Est. Completion: 2028-07-31
Enrollment target: 450 participants
Locations
Stanford University, San Francisco, California, United States
University Of Colorado, Aurora, Colorado, United States
Florida Cancer Specialists - Sarasota, Sarasota, Florida, United States
Winship Cancer Institute, Atlanta, Georgia, United States
Dana Farber Cancer Institute, Boston, Massachusetts, United States
Henry Ford Hospital, Detroit, Michigan, United States
Washington University Medical Center, Division of Oncology, St Louis, Missouri, United States
Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey, United States
The West Clinic - Memphis (Union Ave), Germantown, Tennessee, United States
SCRI Oncology Partners, Nashville, Tennessee, United States
South Texas Accelerated Research Therapeutics (START), San Antonio, Texas, United States
Kinghorn Cancer Centre, Darlinghurst, New South Wales, Australia
Monash Health Monash Medical Centre, Clayton, Victoria, Australia
Linear Clinical Research Ltd, Nedlands, Western Australia, Australia
UZ Antwerpen, Edegem, Belgium
Other microbiome trials you might be interested in